Telix Pharmaceuticals Limited has entered into an asset purchase agreement with antibody engineering company ImaginAb Inc. to acquire a pipeline of next-generation therapeutic candidates, a proprietary novel biologics technology platform, and a protein engineering and discovery research facility to enhance existing innovation capabilities.

This is the latest acquisition from Telix, which also agreed to acquire RLS, a Joint Commission-accredited radiopharmacy network in September.

Pipeline of Next-Gen Therapeutics Candidates

This transaction, which is valued at $45 million, adds a pipeline of early-stage drug candidates against high-value targets including DLL3 and integrin αvβ6, as well as several other novel targets in the discovery stage.

These next-generation drug candidates fit synergistically with Telix’s therapeutics pipeline, enabling expansion to future therapy areas with unmet clinical need. The acquired intellectual property utilizes small engineered antibody formats that enable highly specific cancer targeting, combined with fast tumor uptake and blood clearance. This technology has the potential to be highly effective for imaging and treating tumors with a broad range of radioisotopes, with alpha emitters of particular interest.

Research Facility in CA

The transaction also includes a research facility in California, staffed by a team of discovery, protein engineering and radiopharmaceutical development experts. Together, these assets will provide Telix with further in-house capabilities in antibody engineering and preclinical development, as well as a novel biologics platform to create the next generation of Telix precision medicine and therapeutic products beyond the current clinical-stage pipeline.

Richard Valeix, CEO, Therapeutics, Telix, said, “The combination of a proprietary drug discovery platform, the pipeline of promising theranostic assets, and a talented team of subject matter experts will enhance Telix’s research and innovation capability now and into the future. This acquisition will enable Telix to explore new disease areas with state-of-the-art radiotherapeutic technology.”

Dr. Anna M. Wu, Co-Founder and Board Member, ImaginAb, added, “As the radiopharmaceutical sector gains momentum there is a significant need for targeting agents to be more selective, deliver less off-target radiation, and better match the pharmacology and radiobiology of a given radionuclide. The team’s deep expertise in antibody engineering and the resulting development of a valuable, proprietary platform technology has led to clinical proof-of-concept. Telix is the right partner to unlock the future therapeutic potential of this platform.”